Great article in the NP, very comprehensive.  This is the first time in the approx 4 years I've been in this where we've seen this kind of national exposure.  I suspect that this article may also have accounted for the small uptick in SP and trading volume yesterday.  Will be interested to see what happens on Monday.

More importantly of course are the results of this P2 trial, but if all the publications supporting the application of apabetalone as a bonafide treatment for Covid indications pan out then we should be in for some very interesting months ahead.  It's perhaps also prudent to recognize that there are no guarantees here, but given the recent level of exposure it seems to me that the company is extremely confident of a positive outcome. If that happens then the RVX horse will very much have bolted out of the gate.